The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study.
Peter Martin
Honoraria - Millennium
Research Funding - Millennium
Julie E. Chang
No relevant relationships to disclose
Robert M. Rifkin
Consultant or Advisory Role - Amgen; Celgene; Millennium
Honoraria - Amgen; Celgene; Cephalon; Millennium
Ai-Min Hui
Employment or Leadership Position - Millennium
Deborah Berg
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Guohui Liu
Employment or Leadership Position - Millennium
Alessandra Di Bacco
Employment or Leadership Position - Millennium
Sarit E. Assouline
No relevant relationships to disclose